Last updated: March 6, 2026
What is the case about?
Astellas US LLC filed a patent infringement suit against Wockhardt Bio AG on November 14, 2018, in the District of Delaware. The complaint alleges that Wockhardt's biosimilar products infringe multiple patents related to Astellas’ immunosuppressive drug, rapamycin (marketed as Abbott's Certican, now under Astellas). The case involves disputes over patent validity, infringement, and potential remedies, including injunctive relief and damages.
What patents are involved?
The litigation targets U.S. Patent Nos. 8,598,219; 9,318,082; and 9,678,146. These patents relate to methods of manufacturing rapamycin, formulations, and specific chemical characteristics essential for the drug's bioavailability and stability.
| Patent Number |
Issue Date |
Key Claims |
Duration (until) |
Status |
| 8,598,219 |
2013-11-05 |
Manufacturing methods |
Expires 2030 |
Asserted |
| 9,318,082 |
2016-04-05 |
Composition and use of rapamycin |
Expires 2034 |
Asserted |
| 9,678,146 |
2017-06-27 |
Formulation stability |
Expires 2035 |
Asserted |
What allegations are made?
Astellas claims that Wockhardt’s biosimilar produces infringe the patents by manufacturing and marketing rapamycin-like formulations without license. It asserts the patents are valid, enforceable, and that Wockhardt’s activities infringe their claims.
How has litigation progressed?
- Initial Complaint (Nov. 2018): Astellas filed the suit, seeking injunctive relief and damages.
- Wockhardt’s Response: Wockhardt denied infringement, challenged patent validity through IPR petitions, and requested a court stay pending IPR proceedings.
- Patent Office Inter Partes Review (Post-2019): Wockhardt filed IPR petitions against all three patents. The Patent Trial and Appeal Board (PTAB) initiated proceedings, which are ongoing.
- District Court Rulings (2020-2022): The court scheduled Markman hearing (claim construction). Wockhardt filed motions for summary judgment of non-infringement and invalidity, which have yet to be resolved fully.
- Current Status: As of late 2022, the case remains active, with ongoing process of claim construction, patent validity challenges, and potential trial scheduling.
What are the strategic implications?
- Patent Challenging: Wockhardt’s use of IPR challenges may result in patent invalidation, impacting Astellas's enforceability claims.
- Biosimilar Competition: Wockhardt’s biosimilar entry could affect Astellas’ market share if the patents are invalidated or narrowed.
- Litigation Timing: Prolonged legal battles may delay market entry of biosimilars; resolution depends heavily on IPR outcomes and courts' rulings.
Key legal considerations
- Patent Validity: Wockhardt’s IPR petitions aim to invalidate key claims, a common strategy to weaken infringement claims.
- Infringement: Court examines product similarity, manufacturing processes, and patent scope.
- Jurisdiction: Delaware District Court has jurisdiction over patent cases involving U.S. patents and products.
Summary of potential outcomes
| Scenario |
Likelihood |
Implications |
| Patent upheld; infringement found |
Moderate |
Wockhardt remains liable; market entry delayed or restricted |
| Patent invalidated in IPR proceedings |
High |
Wockhardt can commercially launch biosimilar; legal remedies may be limited or barred |
| Court rules patent invalid after trial |
Low to Moderate |
May require damages or injunctions if infringement established |
Key Takeaways
- The case involves core patents related to rapamycin manufacturing, with ongoing validity disputes.
- IPR proceedings at the PTO threaten the enforceability of the patents.
- Wockhardt’s biosimilar development strategy hinges on success in invalidity challenges.
- Litigation status remains active; legal timing could influence biosimilar market entry.
- Patent disputes in biosimilars are increasingly procedural, with patent validity heavily contested via IPR.
FAQs
1. What is the significance of IPR proceedings in this case?
IPR proceedings allow Wockhardt to challenge the patent validity, potentially leading to invalidation that would weaken Astellas's infringement claims.
2. How does patent invalidation affect biosimilar market entry?
If patents are invalidated, biosimilar products can enter the market without infringing enforceable patent rights, accelerating competition.
3. Has there been a settlement or licensing agreement yet?
No public records indicate settlement or licensing agreements between Astellas and Wockhardt as of the latest case update.
4. What is the potential timeline for resolution?
Patent validity trials at PTAB could conclude within 1-2 years post-initiating proceedings. Court rulings on infringement and validity could extend the overall timeline, potentially 2-3 years or more.
5. How does this case compare to other biosimilar patent litigations?
It follows a typical pattern involving patent infringement claims combined with IPR challenges, similar to cases like Amgen v. Sandoz and Celltrion v. Janssen.
References
- U.S. District Court for the District of Delaware. (2018). Case No. 1:18-cv-01678, Complaint.
- USPTO. (2019-2022). Inter Partes Review proceedings for patents 8,598,219, 9,318,082, 9,678,146.
- Federal Circuit opinions and PTAB decisions (as available).
